284 related articles for article (PubMed ID: 32660456)
41. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
Zargar H; Aning J; Ischia J; So A; Black P
Nat Rev Urol; 2014 Apr; 11(4):220-30. PubMed ID: 24619373
[TBL] [Abstract][Full Text] [Related]
42. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
43. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
44. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
[TBL] [Abstract][Full Text] [Related]
45. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
Onishi T; Sugino Y; Shibahara T; Masui S; Yabana T; Sasaki T
BJU Int; 2017 Feb; 119(2):276-282. PubMed ID: 27444991
[TBL] [Abstract][Full Text] [Related]
46. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
Ather MH; Aziz S; Sulaiman MN
J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
[TBL] [Abstract][Full Text] [Related]
47. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
Ersoy H; Yaytokgil M; Karakoyunlu AN; Topaloglu H; Sagnak L; Ozok HU
Drug Des Devel Ther; 2013; 7():1-6. PubMed ID: 23300343
[TBL] [Abstract][Full Text] [Related]
48. Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Tong S; Hu X; Li Y
Urol Oncol; 2022 Sep; 40(9):412.e1-412.e8. PubMed ID: 35718638
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
Raber M; Buchholz N; Vercesi A; Hendawi NA; Inneo V; Di Paola G; Tessa L; Gazzano G; Viglio A; Hasan IM
Urol Int; 2021; 105(3-4):298-303. PubMed ID: 33333529
[TBL] [Abstract][Full Text] [Related]
50. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
51. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
[TBL] [Abstract][Full Text] [Related]
52. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
[TBL] [Abstract][Full Text] [Related]
53. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
54. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.
De Nunzio C; Carbone A; Albisinni S; Alpi G; Cantiani A; Liberti M; Tubaro A; Iori F
World J Urol; 2011 Aug; 29(4):517-21. PubMed ID: 21594708
[TBL] [Abstract][Full Text] [Related]
55. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Mostafid AH; Porta N; Cresswell J; Griffiths TRL; Kelly JD; Penegar SR; Davenport K; McGrath JS; Campain N; Cooke P; Masood S; Knowles MA; Feber A; Knight A; Catto JWF; Lewis R; Hall E
BJU Int; 2020 Jun; 125(6):817-826. PubMed ID: 32124514
[TBL] [Abstract][Full Text] [Related]
56. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
[TBL] [Abstract][Full Text] [Related]
57. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
58. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
Lan Y; Liu D; Lin M
Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
[TBL] [Abstract][Full Text] [Related]
60. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.
Breyer BN; Whitson JM; Carroll PR; Konety BR
Urol Oncol; 2010; 28(5):510-4. PubMed ID: 19171491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]